Serum osteoprotegerin: Bone or cardiovascular marker in Type 2 diabetes males?

Journal of Endocrinological Investigation

Volumn 36, Issue 1, 2013, Pages 16-20

  Rozas Moreno, P ^a,b   Reyes Garcia R ^a   Garcia Martin A ^a   Varsavsky, M ^a   Garcia Salcedo J A ^a   Munoz Torres M ^a  

^a HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE CIUDAD REAL   (Spain)

Author keywords

Bone metabolism; Cardiovascular disease; OPG; Type 2 diabetes

Indexed keywords

BIOLOGICAL MARKER; OSTEOPROTEGERIN;

ADULT; AORTA CALCIFICATION; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD VESSEL CALCIFICATION; BONE DENSITY; BONE DISEASE; BONE MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY DISEASE; CAROTID PLAQUE; CEREBROVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HYPERTENSION; IMMUNOASSAY; ISCHEMIC HEART DISEASE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROTEIN BLOOD LEVEL; SPINE FRACTURE;

ABSORPTIOMETRY, PHOTON; BIOLOGICAL MARKERS; BLOOD PRESSURE DETERMINATION; BONE DENSITY; BONE DISEASES; CARDIOVASCULAR DISEASES; CAROTID INTIMA-MEDIA THICKNESS; CROSS-SECTIONAL STUDIES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPROTEGERIN; PROGNOSIS; RISK FACTORS;

EID: 84873573825     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/8285     Document Type: Article

References (30)

1. Eckel RH, Kahn R, Robertson RM, Rizza RA. Preventing cardiovascular disease and diabetes: a call to action from the American Diabetes Association and the American Heart Association. Diabetes Care 2006, 29: 1697-9.
2. Malyankar UM, Scatena M, Suchland KL, Yun TJ, Clark EA, Giachelli CM. Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa Bdependent survival factor for endothelial cells. J Biol Chem 2000, 275: 20959-62.
3. Vik A, Mathiesen EB, Brox J, et al. Serum osteoprotegerin is a predictor for incident cardiovascular disease and mortality in a general population: The Tromsø Study. J Thromb Haemost 2011, 9: 638-44.
4. Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 2001, 86: 631-7.
5. Schoppet M, Sattler AM, Schaefer JR, Herzum M, Maisch B, Hofbauer LC. Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab 2003, 88: 1024-8.
6. Rasmussen LM, Tarnow L, Hansen TK, Parving HH, Flyvbjerg A. Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. Eur J Endocrinol 2006, 154: 75-81.
7. Yaturu S, Rains J, Jain SK. Relationship of elevated osteoprotegerin with insulin resistance, CRP, and TNF-alpha levels in men with type 2 diabetes. Cytokine 2008, 44: 168-71.
8. Anand DV, Lim E, Darko D, et al. Determinants of progression of coronary artery calcification in type 2 diabetes role of glycemic control and inflammatory/vascular calcification markers. J Am Coll Cardiol 2007, 50: 2218-25.
9. Avignon A, Sultan A, Piot C, et al. Osteoprotegerin: a novel independent marker for silent myocardial ischemia in asymptomatic diabetic patients. Diabetes Care 2007, 30: 2934-9.
10. Knudsen ST, Foss CH, Poulsen PL, Andersen NH, Mogensen CE, Rasmussen LM. Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. Eur J Endocrinol 2003, 149: 39-42.
11. Anand DV, Lahiri A, Lim E, Hopkins D, Corder R. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol 2006, 47: 1850-7.
12. Reinhard H, Lajer M, Gall MA, et al. Osteoprotegerin and mortality in type 2 diabetic patients. Diabetes Care 2010, 33: 2561-6.
13. Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 2007, 166: 495-505.
14. Indridason OS, Franzson L, Sigurdsson G. Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover. Osteoporos Int 2005,16: 417-23.
15. Stern A, Laughlin GA, Bergstrom J, Barrett-Connor E. The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB legend with bone mineral density in older adults: the Rancho Bernardo study. Eur J Endocrinol 2007, 156: 555-62.
16. Khosla S, Arrighi HM, Melton LJ 3rd, et al. Correlates of osteoprotegerin levels in women and men. Osteoporos Int 2002,13: 394-9.
17. Oh KW, Rhee EJ, LeeWY, et al. Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system are associated with bone metabolism in middle-aged males. Clin Endocrinol (Oxf) 2005, 62: 92-8.
18. Szulc P, Hofbauer LC, Heufelder AE, Roth S, Delmas PD. Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status. J Clin Endocrinol Metab 2001, 86: 3162-5.
19. Mezquita-Raya P, de la Higuera M, Garcia DF, et al. The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women. Osteoporos Int 2005 16: 1368-74.
20. Jørgensen HL, Kusk P, Madsen B, Fenger M, Lauritzen JB. Serum osteoprotegerin (OPG) and the A163G polymorphism in the OPG promoter region are related to peripheral measures of bone mass and fracture odds ratios. J Bone Miner Metab 2004, 22: 132-8.
21. Suzuki K, Kurose T, Takizawa M, et al. Osteoclastic function is accelerated in male patients with type 2 diabetes mellitus: the preventive role of osteoclastogenesis inhibitory factor/osteoprotegerin (OCIF/OPG) on the decrease of bone mineral density. Diabetes Res Clin Pract 2005, 68: 117-25.
22. Kauppila LI, Polak JF, Cupples LA, Hannan MT, Kiel DP, Wilson PW. New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study. Atherosclerosis 1997, 132: 245-50.
23. Erdogan B, Aslan E, Bagis T, et al. Intima-media thickness of the carotid arteries is related to serum osteoprotegerin levels in healthy postmenopausal women. Neurol Res 2004, 26: 658-61.
24. Ishiyama M, Suzuki E, Katsuda J, et al. Associations of coronary artery calcification and carotid intima-media thickness with plasma concentrations of vascular calcification inhibitors in type 2 diabetic patients. Diabetes Res Clin Pract 2009, 85: 189-96.
25. Secchiero P, Corallini F, Pandolfi A, et al. An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction. Am J Pathol 2006, 169: 2236-44.
26. Xiang GD, Pu JH, Zhao LS, Sun HL, Hou J, Yue L. Association between plasma osteoprotegerin concentrations and urinary albumin excretion in Type 2 diabetes. Diabet Med 2009, 26: 397-403.
27. Shargorodsky M, Boaz M, Luckish A, Matas Z, Gavish D, Mashavi M. Osteoprotegerin as an independent marker of subclinical atherosclerosis in osteoporotic postmenopausal women. Atherosclerosis 2009, 204: 608-11.
28. Rogers A, Saleh G, Hannon RA, Greenfield D, Eastell R. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. J Clin Endocrinol Metab 2002, 87: 4470-5.
29. Rogers A, Eastell R. Circulating osteoprotegerin and receptor activator for nuclear factor Kb ligand: Clinical utility in metabolic bone disease assessment. J Clin End Metab 2005, 90: 6323-31.
30. Trouvin AP, Goëb V. Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss. Clin Interv Aging 2010, 5: 345-54.